NCT00150982View on ClinicalTrials.gov

Alefacept Mechanism of Action in Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2003

Study Completion Date

February 28, 2005

Conditions
Psoriasis
Interventions
DRUG

Mechanism of action of alefacept

Trial Locations (1)

08903

UMDNJ Clinical Research Center, New Brunswick

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

University of Medicine and Dentistry of New Jersey

OTHER

NCT00150982 - Alefacept Mechanism of Action in Psoriasis | Biotech Hunter | Biotech Hunter